Litcius/Paper detail

TCR-T Immunotherapy: The Challenges and Solutions

Yating Liu, Xin Yan, Fan Zhang, Xiaoxia Zhang, Futian Tang, Zhijian Han, Yumin Li

2022Frontiers in Oncology114 citationsDOIOpen Access PDF

Abstract

T cell receptor-engineered T cell (TCR-T) therapy is free from the limit of surface antigen expression of the target cells, which is a potential cellular immunotherapy for cancer treatment. Significant advances in the treatment of hematologic malignancies with cellular immunotherapy have aroused the interest of researchers in the treatment of solid tumors. Nevertheless, the overall efficacy of TCR-T cell immunotherapy in solid tumors was not significantly high when compared with hematological malignancies. In this article, we pay attention to the barriers of TCR-T cell immunotherapy for solid tumors, as well as the strategies affecting the efficacy of TCR-T cell immunotherapy. To provide some reference for researchers to better overcome the impact of TCR-T cell efficiency in solid tumors.

Topics & Concepts

ImmunotherapyT-cell receptorCancer immunotherapyT cellMedicineCancer researchSolid tumorAntigenCancerImmunologyImmune systemInternal medicineCAR-T cell therapy researchImmunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers
TCR-T Immunotherapy: The Challenges and Solutions | Litcius